Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The outer membrane of Gram-negative bacteria is a specialized asymmetric lipid bilayer that serves as the primary defense mechanism against environmental threats and antibiotics. The outer leaflet is predominantly composed of lipopolysaccharide (LPS), a complex glycolipid consisting of Lipid A, a core oligosaccharide, and an O-antigen, while the inner leaflet contains phospholipids (Raetz & Whitfield, 2002). LPS is essential for bacterial viability and acts as a potent endotoxin, triggering systemic inflammatory responses via the Toll-like receptor 4 (TLR4) complex in humans (Alexander & Rietschel, 2001). This target is clinically significant because it is the primary site of action for last-resort antibiotics like polymyxins. Polymyxins bind to the negatively charged phosphate groups of Lipid A and adjacent phospholipids, displacing stabilizing divalent cations and causing lethal membrane disruption (Poirel et al., 2017). Understanding this target is crucial for developing new antimicrobial strategies to combat multi-drug resistant Gram-negative pathogens (Zhanel et al., 2019).
Cationic cyclic peptides, such as polymyxins, interact electrostatically with the negatively charged phosphate groups of the Lipid A component of LPS and adjacent phospholipids (Poirel et al., 2017). This interaction leads to the displacement of divalent cations (Mg2+ and Ca2+) that normally stabilize the outer membrane structure. The resulting destabilization increases membrane permeability, allowing the drug to penetrate the periplasm and disrupt the inner cytoplasmic membrane, leading to the leakage of intracellular contents and cell death (StatPearls, 2023).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative bacterial outer membrane lipopolysaccharide and phospholipids (LPS).